Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 24, 2024 12:29pm

95 Views

Post# 36194680

RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

August 01, 2024 - " With the IRA creating a longer window for price negotiation on large molecule drugs—13 years compared to 9 years for small molecule drugs—companies also have a golden opportunity to drive growth through biologics. This extended protection period allows companies to recoup development costs, generate more revenue, and solidify their market position, making biologics a highly attractive area for investment.

Accelerating innovation in biotech through M&As

When done right, M&As can be a powerful driver of innovation in the pharmaceutical industry. .... For pharma companies, acquiring a biotech can be a more cost-effective way to access innovative therapies without the extensive time and expense required to develop new drugs from scratch.

From the cancer drug Keytruda to the autoimmune disease medication Humira, many of today’s top-selling drugs trace their success to M&As that accelerated their research, development, and market entry. As pharma companies actively seek to expand their pipelines, biotechs that align with their priorities become increasingly attractive targets or strategic partners.